InMed Pharmaceuticals Announces Merger with Mentari Therapeutics

InMed Pharmaceuticals (INM) announced a stock-based merger with migraine drug developer Mentari Therapeutics, causing INM shares to rise sharply. The new entity will trade on Nasdaq under a different ticker symbol, but existing InMed shareholders are expected to own only about 1.51% of the combined company post-merger.

By Wajeeh Khan Wed, May 20, 2026 at 8:01 PM GMT+3 2 min read · Yahoo Finance · May 20, 2026, 17:01 UTC

InMed Pharmaceuticals Announces Merger with Mentari Therapeutics

Tickers: $INM

Topics: mergers shareholder concerns stock price movement

Read the full article at Yahoo Finance

More World news

Allstate Announces Quarterly Dividend of $1.08 Per Share PR Newswire · November 12, 2026, 17:38 UTC
Stephanie Link Shifts AI Allocation from Nvidia to Micron Technology Following CEO Resignation CNBC · November 12, 2026, 17:37 UTC
Boyd Group Reports 28% Revenue Growth and $90 Million in Cost Savings for Q3 2026 Motley Fool · November 12, 2026, 17:33 UTC
Hugging Face CEO Reaffirms Commitment to Open-Source AI Following Nvidia CEO Jensen Huang's Departure TechCrunch · November 12, 2026, 17:36 UTC
Marimed Reports Record $44.2M Quarterly Revenue and Targets 2027 New York Launch Seeking Alpha · November 12, 2026, 17:30 UTC
Nebius Group Reports Massive Q3 2026 Revenue Growth Driven by AI Cloud Expansion Motley Fool · November 12, 2026, 17:29 UTC
Reagan Institute Launches Society of Fellows to Support Early Career Scholars PR Newswire · November 12, 2026, 17:32 UTC
Global Asset Management Group Signs LOI for $100 Million Affordable Housing Portfolio in Washington, D.C. PR Newswire · November 12, 2026, 17:30 UTC
U.S. Air Conditioner and Heat Pump Shipments Increase 27.3% in September Seeking Alpha · November 12, 2026, 17:27 UTC
Nvidia CEO Jensen Huang Resigns Amid Intelligence Probe Seeking Alpha · November 12, 2026, 17:27 UTC